Resolution Therapeutics

Amir Hefni
Prof. Stuart Forbes
Prof. John Campbell
% Shareholding
Number of employees
Extension of £26.6m Series A announced in April 2022

Unless stated all financials at 31 December 2023

Resolution website

Resolution is developing macrophage cell therapies to repair inflammatory organ damage.

Syncona co-founded Resolution following a two year collaboration with researchers at the University of Edinburgh and the Scottish National Blood Transfusion Service.

Resolution is developing macrophage cell therapies to repair inflammatory organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury; the company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings.

Investment thesis

  • An opportunity to create the leading inflammation-focused macrophage cell therapy business, focusing initially on treatment of liver cirrhosis. The goal is to repair the livers of patients sufficiently to reduce the risk of decompensation. Future opportunity lies in lung and kidney repair in chronic fibrotic disease.

Unmet medical need

  • Chronic inflammatory organ damage represents a major burden to patients. If left untreated, liver cirrhosis will often progress to decompensation through significant loss of liver function. Today there are no efficacious treatments to prevent deterioration in the latter stages of the disease, thus leaving costly and burdensome liver transplantation often as the only option.

Market opportunity

  • ­New diagnoses of liver cirrhosis affect hundreds of individuals per million of population 

Syncona team

Edward Hodgkin

Edward Hodgkin

Edward Hodgkin is a Managing Partner of Syncona Investment Management Ltd. He is currently the Chair of Mosaic Therapeutics and a Board member of Resolution Therapeutics and OMass Therapeutics. He was also previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL), and the former CEO of Resolution Therapeutics. Within the Syncona life science team, he is involved in creation…
View Edward's biography
Board member
Gonzalo Garcia

Gonzalo Garcia

Gonzalo is an Investment Partner of Syncona Investment Management Ltd. At Syncona, Gonzalo was part of the founding team at Resolution Therapeutics, a macrophage cell therapy company, where he was Chief of Staff and remains a Board Observer. He is now focused on new company creation, centred primarily on innovative concepts in biologics. Previously, Gonzalo was a Project Leader at Boston Consultin…
View Gonzalo's biography
Board observer
Lisa Bright

Lisa Bright

Lisa is an Executive Partner at Syncona Investment Management Ltd, and serves as Chair of Syncona portfolio company Resolution Therapeutics. Lisa is a senior commercial leader and board member with over 30 years’ experience in biopharmaceuticals, serving in executive and general management roles where she has developed expertise in launching innovative specialty medicines. Most recently Lisa serve…
View Lisa's biography
Gwenaelle Pemberton

Gwenaelle Pemberton

Gwenaelle is a Regulatory Advisor to Syncona Investment Management Ltd. Gwenaelle is a senior regulatory leader with over 30 years’ experience in global regulatory strategy in biopharma. Most recently, Gwenaelle was Vice President International Regulatory Affairs at Gilead, leading the International Regulatory Group which was responsible for regulatory activities worldwide, excluding the US. Gwena…
View Gwenaelle's biography

Resolution Therapeutics leaders and founders

Other pre-clinical portfolio companies